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Any aetiological agent or mechanism implicated in AS must provide an explanation for the link with HLA-B27. An amino acid sequence homology, QTDRED, found in the variable region of B*2705, (residues 72-77) and the KP2 component of Klebsiella pneumoniae nitrogenase enzyme (residues 188-193) has been reported. 2 Furthermore, AS patients were shown to have increased concentrations of antibodies to a homologous sequence of both B*2705 2 3 and the KP2 component of K pneumoniae nitrogenase reductase 2 although some workers have been unable to confirm these results. 4 Antibody aYnity is often lower with peptide sequences compared with binding by the native protein and this could be because of conformational changes between peptide and the native protein molecule, thereby accounting for these diVerences in reactivity.
In the light of these conflicting findings, this study was undertaken to measure antibodies to the native KP2 component of nitrogenase reductase enzyme of K pneumoniae, to determine if it has a part to play in the development of disease, and whether antinitrogenase antibodies are correlated with C reactive protein (CRP) concentrations.
Serum samples were obtained from AS patients attending the AS Research Clinic at the Middlesex Hospital, and rheumatoid arthritis (RA) patients attending the Rheumatology Department at the Lister Hospital, Stevenage. Healthy control samples were supplied by the Blood Transfusion Service, London. The diagnosis of AS was according to the New York criteria and that of RA by the American Rheumatism Association.
In the study, IgG, IgA, and IgM immunoglobulin antibodies were measured in 200 subjects against K pneumoniae nitrogenase reductase. The groups examined were as follows: 100 patients with AS (71 male, 29 female, mean age 47 years); 50 RA patients (15 male, 35 female, mean age 57 years), and 50 healthy control subjects (30 male, 20 female, mean age 44 years).
The KP2 component of Klebsiella nitrogenase, which contains the QTDRED sequence, was provided by Dr Martin Buck, of the Nitrogen Fixation Laboratory in Sussex University and purified as previously described. 5 Antibody levels against the KP2 component of K pneumoniae nitrogenase reductase were measured by enzyme linked immunosorbent assay (ELISA) as previously described. 6 All assays were carried out under code, so that the status of each serum sample under investigation was not known to the tester. CRP concentrations were determined by the single radial immunodiVusion method of Mancini et al 7 and the results expressed as mg/l of serum. The mean optical density (OD) units of IgG, IgA, and IgM immunoglobulin antibodies against the KP2 component of K pneumoniae nitrogenase reductase in diVerent groups were compared with Student's t test. The association between the anti-KP2 component antibodies and CRP was analysed using Pearson's correlation analysis.
We found that the AS patients had significantly increased antibody concentrations of the IgG (mean (SEM)) (0.32 (0.01), OD units) (t = 6.12; p<0.001) and IgA class (0.42 (0.02), OD units) (t = 8.84; p<0.001) to KP2 component of K pneumoniae nitrogenase reductase compared with the healthy control group. In addition, AS patients had significantly increased antibody concentrations of the IgG (0.32 (0.01), OD units) (t = 4.33; p<0.001) and IgA class (0.42 (0.02), OD units) (t = 7.97; p<0.001) to the KP2 component of K pneumoniae nitrogenase reductase compared with the RA patients. However, there was no significant increase in IgM antibody concentrations against the nitrogenase reductase protein (table 1) . The RA patients showed no significant antibody increases in IgG, IgA or IgM classes with respect to control subjects. The mean CRP concentrations were 21.6 mg/l (SEM) (2.4) in the AS patients, 39.1 mg/l (3.9) in the RA group, and 6.9 mg/l (1.7) in the healthy control group.
There was a significant correlation between IgG (r = +0.385, p<0.001) ( fig 1A) and IgA (r = +0.442, p<0.001) ( fig 1B) Lack of association between HLA DRB1* alleles and RS3PE syndrome
In 1985, McCarty and colleagues reported a series of patients characterised by symmetrical and acute synovitis, marked pitting oedema, seronegativity resulting from the absence of rheumatoid factors (RF), increased acute phased reactants, lack of bony erosions on radiography, and benign and short course (RS3PE syndrome: remitting seronegative symmetrical synovitis with pitting oedema). 1 Most patients were older men. A pitting oedema was also observed in other conditions (polymyalgia rheumatica (PMR) and late onset peripheral spondylarthropathy (LOPS)). 2 3 Whether the RS3PE syndrome represents a distinct clinical entity remains controversial.
This syndrome was initially reported to be associated with HLA-B (B7) rather than HLA-DR (DR4) antigens. 1 4 Recently, an association with HLA-A2 was reported. 5 The association between RA and HLA-DRB1* alleles expressing the shared epitope (SE) (*0401, *0404, *0405, *0408, *0101, *0102, *1001, *1402) is well established. Older age onset RA and seronegative RA are known to be poorly or slightly related to DR4. 6 7 Futhermore, an association was reported between the HLA-DR antigens that contain the SE and PMR. 8 We studied the HLA-DR polymorphism in RS3PE syndrome patients: HLA-DRB1* typing (PCR-SSO; people who typed as HLA-DR1 or DR4 had a subtyping for HLA-DRB1*0101 to *0104 and HLA DRB1 *0401 to *0422) was performed in 12 white patients (eight male and four female; mean age: 72, range: 62-84) admitted to our department during the past 10 years. They all had typical RS3PE syndrome with acute onset symmetrical polysynovitis involving the wrists, metacarpophalangeal and proximal interphalangeal joints, tenosynovitis of the flexor of the hands, and a marked pitting oedema. Three patients had a carpal tunnel syndrome and one had had a PMR five years before this polyarthritis with pitting oedema resolving with corticosteroid treatment. For seven patients, shoulders and/or pelvic girdle were aVected. The erythrocyte sedimentation rate (ESR) ranged from 20 to 100 mm 1st h and the C reactive protein (CRP) concentration was between 5 and 170 mg/l. RF (nephelometry) were negative as well as antinuclear antibodies. No bony erosions were observed on both hand and foot radiographs. A synovial biopsy was performed in three cases giving non-specific synovitis. All the patients were treated with corticosteroids (<10 mg/ day) with resolution of the oedema after one month. The mean duration of this treatment was 50 months (range 6 months-10 years). All the patients were contacted for long term follow up (mean period: 53 months; range: 6 months-10 years). The prognosis was good and no malignancy occurred during this period. Two patients had one relapse of polyarthritis with prominent pitting oedema and they developed a PMR and a polymyositis, respectively. RF remained negative in all the patients and no hand bony erosions were observed on the outcome radiographs.
Four patients were DRB1*04 (*0401:1, *0404:2, *0405:1), one DRB1*01, and one DRB1*1001 (table 1) . In our region, the frequencies of HLA DRB1*0401, *0404, *0405, and *0101 were determined to be 7.7%, 2.8%, 2.8%, and 13.4% in a control group of 104 healthy subjects. The frequencies of these alleles in 104 RA patients (15 seronegative, 89 seropositive) were *0401: 26.9% ( 2 test, p < 0.0001), *0404: 12.5% (p=0.04), *0405: 4.8% (p = 0.8), and *0101: 34.6 % (p = 0.03). Frequencies of all the allelic subtypes that contained the SE tended to be increased in RS3PE patients (41.6%) and seronegative RA (53.3%) but this increase was not statistically significant (controls : 35.8%; 2 test: p = 0.8 and p = 0.29, respectively) (table 1). In addition, there were no significant diVerences in the age of onset of acute polyarthritis, ESR, CRP concentration, duration of corticosteroid treament or PMR-like clinical presentation (shoulder and/or pelvic girdle pain) between RS3PE patients with and without the SE.
Our data suggest that there is no association between HLA-DRB1* alleles and RS3PE syndrome. A slight increase in DRB1* alleles encompassing the SE was observed in this series, but without significance. The overrepresentation of the SE in the RA group argues against a poor expression of this motif in our RA patients. As it has been previously reported, HLA-DRB1*01 and *04 were slightly increased in our seronegative RA patients. In the RS3PE patients, there was no influence of the SE on the clinical presentation. In general, all of our patients had a favourable outcome and none had developed bony erosions on radiographs or typical RA. Thus, it may be suggested that this good outcome could be related to the poor expression of the shared motif in these patients. It may also be advanced that HLA-DRB1* typing in patients with RS3PE syndrome provides no useful information. As a link with HLA B7 and/or A2 has been reported, analysis of HLA A and B locus may only be performed in RS3PE syndrome. The long term follow up of patients with RS3PE syndrome has provided the diagnosis of more well defined conditions such as RA, PMR, spondylarthropathies, and malignancies.
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As it has been previously suggested, 9 10 RS3PE could be considered as a heterogenous syndrome and this may explain the lack of association with a specific HLA-DR antigen. 
Rupture of a non-aneurysmatic aortic trunk in a patient with giant cell arteritis
Giant cell arteritis is a chronic, granulomatous inflammation of the temporal arteries that aVects persons over the age of 50. 1 Temporal arteritis is sometimes the first evident sign of a more disseminated disease and involvement of all the larger arteries including the aorta has been observed. 2 Many studies describe appearance of murmurs and the formation of aortic aneurysms in patients suVering from temporal arteritis. 3 Weak extremity pulses, arm claudication and colour changes of Raynaud's phenomenon type may occur, symptoms resulting from the narrowing or occlusion of branches of the thoracic aorta. 2 Death from rupture of aneurysms in giant cell arteritis is well documented. 3 4 It has also been suggested that the extraarticular disease polymyalgia rheumatica 5 is an expression of the generalised form of giant cell arteritis and the name polymyalgia arteritica may be more appropriate. A 74 year old woman was admitted to the university hospital in Lund because of tenderness over the right masseter muscle. It propagated towards the temporal region and spread similarly on the left side and over the back of the head. On admission the erythrocyte sedimentation rate (ESR) was 42 mm 1st h and serum electrophoretic analysis indicated slight inflammatory activity. The patient presented with a minor exophtalmus resulting from an earlier episode of Grave's disease, but was otherwise previously healthy and in good physical condition. The subcutaneous temporal vessels were swollen and tender. On the diagnosis of probable temporal arteritis, 30 mg/day of prednisolone were prescribed. A biopsy, showing inflammatory cell infiltrates in the arterial wall, verified the diagnosis. The ESR decreased and the symptoms declined and the prednisolone was reduced to 5 mg/day. On several check ups over five years, there were no signs or symptoms of active disease and the ESR was at all times below 15 mm 1st h. At the age of 79, the patient collapsed during a walk and was declared dead upon arrival of the ambulance.
Necropsy revealed in the aortic trunk, 3 cm above the valvular plane, a rupture within a small area of pronounced wall thinning (< 0.5 mm) and haemopericardium. There were no aortic aneurysm formation or dissection and only minor atheromatotic plaques. Microscopically, the aorta and the left common carotide unexpectedly showed widespread infiltrates of lymphocytes, plasma cells, and scattered multinucleated giant cells (fig 1) . The inflammation was intense in the aorta, showing cell infiltrates in all vessel wall layers, accompanied by oedema/necrosis and multifocal pronounced dissolution of the elastic fibres (fig 2) , shown by staining for collagen IV and laminin. Close to the rupture, one arteriole was totally obliterated by inflammatory cells. Some minor arteriosclerotic lesions were seen and focal precipitation of metachromatic material, representing myxoid degeneration. The remaining temporal artery was not examined, as active arteritis had not been suspected at the time of necropsy.
Pathogenetically, we suggest that the intense aortic inflammation dissolved the elastic fibres, and attenuated the wall. It also obliterated some of the aVerent arterioles (vasae vasorum), leading to multifocal ischaemic wall necrosis, followed by rupture of the vessel wall, without prior formation of an aneurysm. Despite focally intense inflammatory infiltrates, it is impossible to determine whether this was an acute exacerbation of the disease or part of a chronic, active inflammation. Clinically, however, there was no sign of disease activation. It is well known that giant cell arteritis can lead to death by rupture of aortic aneurysm. 3 In this patient, there was inflammatory and ischaemic aortic wall necrosis without an aneurysm. This has, to our knowledge, not been reported before.
We are indebted to Professor Emeritus Nils Jonsson, for his critical examination of this report.
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MATTERS ARISING
Serum uric acid in acute gout
Logan and colleagues recently reemphasised that serum uric acid is often within the normal range during the acute episode of gout and suggested that serum urate invariably falls during episodes. 1 We too have studied the frequency of normal uric acid concentrations during an acute episode. 2 Thirty nine per cent of our patients as compared with 43% of Logan's patients had serum uric acid concentrations within the normal range during the acute episode. In contrast with the statement by Logan and colleagues that serum urate invariably falls during episode we found that serum uric acid concentrations can either be higher or lowerwithacuteepisodesthanduringtheintercritical period. Patients receiving long term allopurinol treatment tended to be more likely to have lower serum uric acid during the acute episode (p<0.01). Patients not receiving allopurinol treatment tended to have higher serum uric acid concentrations during the acute gouty episodes than during the interim (p<0.005). More study is needed with more sequential observations examining the relation between timing of episodes and changes in serum uric acid. NAOMI 
Authors' reply
Schlesinger and colleagues confirm our findings on the frequency of a normal serum uric acid in acute gout. However, they have misread our statement concerning the comparative serum uric acid values during and between episodes. On the basis that in 70% of patients the serum uric acid was lower during the acute episode we concluded that the serum uric acid "usually" falls at that time but not "invariably" as misquoted by Schlesinger. Their error is understandable (and forgivable!) as we did state in an earlier communication 1 that the serum uric acid "almost invariably" falls during acute gout. We supported this statement with the data in figure 1 that appeared in our presentation but not the published abstract. We do agree that more sequential studies of this kind are needed before deciding on the correct qualifying adverb. 
Clinical guidelines
Suarez-Almazor and Russell raise several important points in their excellent review about the plethora of clinical guidelines issued by various oYcial, unoYcial, learned or merely pretentious bodies. The potential consumer (usually a full time clinician) is advised to evaluate the soundness of the guidelines on the basis of the strength of evidence on which the guidelines are based (that is, double blind randomised trials versus consensus of opinion) and how clearly the supporting evidence is described.
In reality most guidelines are like an old staircase, with some solidly anchored steps, interspersed with others supported by nothing more than the rickety whim of current opinion. In the end therefore, before deciding that it is safe to climb the stairs, the consumer places his trust more in the pedigree of the authors than in anything else.
More fundamental than "safety" however is the question of why it was built in the first place. This is very seldom stated, though it is generally assumed to be a worthy reason, which all would share.
Even worthy reasons can have competing eVects however, and unless the primary goal was clearly identified at inception and its priority maintained against the sometimes competing interests of other worthy goals throughout the development of the guidelines, it can be very diYcult to discern the distortions that might have been introduced when you only see the final product.
Guidelines written for the primary purpose of reducing practice variability for cost management, or as a perceived protection against litigation, may also achieve a benefit in reducing morbidity but are likely to be diVerent from guidelines written for the primary purpose of morbidity or mortality reduction, with cost containment the incidental benefit.
For example, guidelines with the title of "postoperative care after knee replacement" are going to diVer in important detail if written for the primary purpose of reducing length of hospital stay, from ones written with the primary aim of maximising functional outcome.
It should be incumbent on the authors of guidelines to state what their primary purpose was in writing them, which in a manner analogous to a well structured study with an a priori defined primary outcome measure, can then be subjected to assessment.
In the absence of such a statement, caveat emptor, you may be climbing the wrong staircase. 
